Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
CANO HEALTH Aktie jetzt für 0€ handeln |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
INTUITIVE SURGICAL | 459,45 | +0,81 % | What to Expect From Intuitive Surgical's Next Quarterly Earnings Report | ||
UNITEDHEALTH | 264,65 | +0,25 % | United-Health-Konkurrent: Kaufchance? Diese Aktie ist einfach viel zu billig! | © Foto: Google GeminiDie Aktie des US-Krankenversicherers Centene ist so günstig wie lange nicht. Das gilt nicht nur für die Aktie, sondern auch die Bewertung des Unternehmens.In der US-Krankenversicherungsbranche... ► Artikel lesen | |
ROKU | 74,75 | +0,66 % | Should You Buy Roku Stock After Its Partnership With Amazon? | ||
ATOSSA THERAPEUTICS | 0,745 | -2,49 % | Atossa Genetics Year-end 2024 slides: (Z)-endoxifen shows promise, expenses decline | ||
EVOFEM BIOSCIENCES | - | - | Windtree Therapeutics: Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel | Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of... ► Artikel lesen | |
CENTENE | 45,785 | -0,75 % | Centene-Aktie läuft heute schlechter (46,0076 €) | Im Minus liegt aktuell der Anteilsschein von Centene . Die Aktie kostete zuletzt 53,62 US-Dollar. Ein Preisabschlag in Höhe von 43 Cent müssen derzeit die Aktionäre von Centene hinnehmen. Für das Papier... ► Artikel lesen | |
VERU | 0,506 | -1,94 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen | |
QUIDELORTHO | 24,600 | -0,81 % | QuidelOrtho Corp - S-8, Securities to be offered to employees in employee benefit plans | ||
TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China | Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest... ► Artikel lesen | |
NANO-X IMAGING | 5,225 | -0,10 % | Nanox Imaging to Present at the Investor Summit Virtual on June 10, 2025 | PETACH TIKVA, ISRAEL / ACCESS Newswire / June 9, 2025 / Nanox Imaging announced that Ran Daniel, Chief Financial Officer, will be presenting at the Investor Summit Virtual taking place on June 10.About... ► Artikel lesen | |
FULGENT GENETICS | 16,900 | 0,00 % | Fulgent genetics targets $310M core revenue in 2025 with strong growth in diagnostics and pathology | ||
LANTHEUS | 69,90 | +0,40 % | Lantheus Holdings, Inc.: Lantheus Announces Sale of SPECT Business to SHINE Technologies | Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business SHINE will acquire products TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite®... ► Artikel lesen | |
PERSPECTIVE THERAPEUTICS | 3,000 | -6,83 % | Perspective Therapeutics, Inc. - 8-K, Current Report | ||
AMN HEALTHCARE SERVICES | 17,500 | +4,79 % | AMN Healthcare Services Inc: Celia Huber Joins AMN Healthcare Board of Directors | ||
OMNICELL | 25,000 | -0,79 % | Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results | FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery... ► Artikel lesen |